MedTrace Logo

Comparison of Diagnostic Sensitivity Between ctDNA Methylation and CEA in Colorectal Cancer

NCT05558436 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 662

Last updated 2024-05-10

No results posted yet for this study

Summary

This is a prospective diagnostic study. This study is to compare the performance between circulating tumor DNA (ctDNA) methylation and carcinoembryonic antigen (CEA) in detecting colorectal tumor. Firstly, based on the identification of differential ctDNA methylation biomarkers, the diagnostic model is established and the diagnostic performance was compared with that of CEA. Secondly, the stage stratification model was established preliminarily based on differential ctDNA methylation biomarkers and the performance was also compared with that of CEA.

Conditions

  • Colorectal Tumor

Interventions

DIAGNOSTIC_TEST

Genome-wide methylation profiling

Detection for colorectal tumor-specific ctDNA methylation biomarkers

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Jun Yan, M.D., Ph.D. · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-05-01
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05558436 on ClinicalTrials.gov